Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$254.1M
149M shares
52-week range
$0.16 – $3.39
47% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
17.69%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.1M | $8.1M | $0 | $0 | $0 | $0 | $0 | $1.4M |
| Cost of revenue | $18.5M | $23.8M | $554.1K | $262.1K | $204.7K | $44.2K | $113.9K | $756.3K |
| Gross profit | $0 | −$15.7M | −$554.1K | −$262.1K | −$204.7K | −$44.2K | −$113.9K | $657.2K |
| Gross margin | 0.0% | -192.2% | — | — | — | — | — | 46.5% |
| R&D | $18.5M | $23.8M | $26.3M | $39.0M | $42.3M | $26.5M | $41.8M | $27.18T |
| Operating income | −$29.6M | −$36.3M | −$36.8M | −$51.7M | −$63.1M | −$53.1M | −$71.7M | −$67.1M |
| EBITDA | −$26.8M | −$31.1M | −$36.2M | −$51.5M | −$64.4M | −$57.4M | −$72.1M | −$63.6M |
| Net income | −$30.1M | −$34.5M | −$35.2M | −$53.2M | −$66.1M | −$59.0M | −$75.4M | −$62.4M |
| Net margin | -974.5% | -423.8% | — | — | — | — | — | -4416.2% |
| EPS (diluted) | -85.00 | -39.60 | -13.47 | -6.96 | -6.23 | -4.72 | -4.06 | -1.79 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $14M | $-0.49 | $-0.52–$-0.43 | 1 |
| 2027 | $46M | $-0.23 | $-0.34–$-0.12 | 3 |
| 2028 | $23M | $-0.15 | $-0.45–$-0.02 | 1 |
| 2029 | $30M | $-0.12 | $-0.36–$-0.01 | 1 |
Forward consensus · source: Financial Modeling Prep
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
www.outlooktherapeutics.comNo one on the platform currently holds OTLK.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 255,157 | $52.5K |
| Execution date | Ratio |
|---|---|
| 2024-03-14 | 1-for-20reverse |
| 2019-03-18 | 1-for-8reverse |
No one on the platform has traded OTLK yet.
| $15M |
| — |
| IOBTIO Biotech, Inc. | $0.01 | -27.59% | $885690 | — |
| IPSCCentury Therapeutics, Inc. | $2.41 | +3.88% | $209M | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
@SlvrShroud94 @KavaStocks @Keekster1 $OTLK is a great rotation as $SLS has entered odd waters. And @KavaStocks common misconception, but stem cell transplant ineligibity speaks solely to enrollment. Based on trial protocol, patients in REGAL can become eligible for transplant for the following reasons: 1) Become healthy enough for transplant 2) Patient decides to pursue Stem Cell Transplant after previously declining it 3) A donor becomes available Hope this helps and is a very underrated element of the REGAL narrative. Cheers!
View on StockTwits ↗$OTLK Ross LundRoss Lund • 3rd+3rd+ Pharmaceutical & Biotech Finance Leader. What do you think? I think this is a very strong move for our beloved stock.
View on StockTwits ↗$OTLK GOD’ will 2,50$ coming before 29th.
View on StockTwits ↗$OTLK do you know how many biosims are out there? Eylea has 3 biosims. Nobody wants bevaci biosim
View on StockTwits ↗$OTLK for the new people to this binary play: Snapshot: Very high volatility (beta ~1) Recent range: $0.16 → $3.39 Major catalyst: FDA PDUFA decision expected July 29, 2026 Recent developments: FDA accepted resubmitted BLA (major positive step) FDA Office of New Drugs concluded there IS substantial evidence of effectiveness That directly reversed the prior “insufficient efficacy” stance FDA said no new trials are required Nasdaq compliance regained (removes delisting risk) Opportunity! 🚀💰
View on StockTwits ↗$OTLK @TickrTalk0007 thats ok. Old is GOLD. LYTENAVA is the one and only 1st eye medicine going for an US FDA Approval. So, demand will be huge. END OF 2026 and next year 2027, we will know when the sales starts pickit up for LYTENAVA.
View on StockTwits ↗$AMZN $DELL $MU $NVDA $OTLK they got rejects 5 times. This drug is 8yrs late to the party
View on StockTwits ↗$OTLK EARLY CHANCES FOR AN APPROVAL IS SO HIGH aswell - 1000% now
View on StockTwits ↗$OTLK Only 29 exact days left (4 and half weeks only) for an US FDA Big LYTENAVA approval. Possible we could see the big upward momentum slowly with $2.50 INCOMING.. $NVDA $MU $DELL $AMZN
View on StockTwits ↗@Sunnym_15 hopefully its sooner than later im trying to juggle this stock and $OTLK but keep going all in on both taking small profits
View on StockTwits ↗$OTLK sold half but holding 100k or 200k through Pdufa Come on FDA 🥵
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.